BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2023 1:35:50 PM | Browse: 551 | Download: 1164
 |
Received |
|
2022-12-09 15:45 |
|
Peer-Review Started |
|
2022-12-09 15:48 |
|
First Decision by Editorial Office Director |
|
2022-12-24 22:37 |
|
Return for Revision |
|
2022-12-24 22:37 |
|
Revised |
|
2022-12-30 19:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-01-18 03:19 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-01-18 23:27 |
|
Articles in Press |
|
2023-01-18 23:27 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-01-19 08:11 |
|
Publish the Manuscript Online |
|
2023-02-24 13:35 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rishi Arora, Michelle T Martin, Justin Boike and Sonalie Patel |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sonalie Patel, PharmD, Pharmacist, Division of Hepatology , Northwestern Medicine, 676 N St. Clair 560, Chicago, IL 60611, United States. sonalie.patel@nm.org |
| Key Words |
Hepatitis C virus; Direct-acting antivirals; Liver transplantation; Glecaprevir/pibrentasvir; Sofosbuvir; Ribavirin |
| Core Tip |
In the post-liver transplant population, current national guidance only recommends sofosbuvir/velpatasvir/voxilaprevir, with or without ribavirin, for recurrent hepatitis C virus treatment in direct-acting antiviral-experienced patients. We describe an alternative regimen of glecaprevir/pibrentasvir in combination with sofosbuvir that resulted in sustained virologic response without treatment-related adverse events. |
| Publish Date |
2023-02-24 13:35 |
| Citation |
Arora R, Martin MT, Boike J, Patel S. Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment. World J Hepatol 2023; 15(2): 318-320 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i2/318.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i2.318 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
